This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration With AbbVie

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has further expanded its antibody-drug conjugate (ADC) collaboration with AbbVie (NYSE: ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25 million for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine (PBD) dimer ADC technology and EC-mAb site-specific conjugation technology. In addition, Seattle Genetics could receive up to approximately $255 million in potential license fees and milestone payments per target, upon achieving predetermined development and commercial objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products.

“Seattle Genetics continues to advance the field of ADCs through the development and optimization of innovative approaches to empowering antibodies, such as our proprietary EC-mAb and potent PBD-based ADC technologies, both of which are utilized in our pipeline programs SGN-CD33A and SGN-CD70A,” said Natasha Hernday, Vice President, Corporate Development at Seattle Genetics. “By collaborating with companies such as AbbVie, we are expanding the reach of our ADC technology advancements to make novel targeted therapies available for cancer patients.”

Prior to its spinoff of AbbVie, Abbott made an upfront payment of $8 million to enter into an original ADC deal with Seattle Genetics in March 2011, and paid an additional $25 million to expand the collaboration in October 2012. AbbVie is responsible for research, product development, manufacturing and commercialization of any ADC products under the collaboration. In addition to the upfront payment and potential milestone payments and royalties, Seattle Genetics will receive annual maintenance fees and research support payments for assistance provided to AbbVie in developing ADCs.

ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells, resulting in targeted cell death. Seattle Genetics’ linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. With 15 years of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and PBD dimers, and stable linker systems that attach these cytotoxic agents to the antibody. Of the approximately 30 ADC candidates in clinical development, more than 18 utilize Seattle Genetics’ proprietary ADC technology.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs